Spero Therapeutics (SPRO) Shares Outstanding (Weighted Average) (2016 - 2026)
Spero Therapeutics posted quarterly Shares Outstanding (Weighted Average) of $57.3 million for Q1 2026, up 3.44% year-on-year from $55.4 million in Q1 2025, and up 2.25% on a QoQ basis from $56.0 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $57.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.44% year-over-year to $57.3 million; the trailing twelve-month figure through Mar 2026 stood at $57.3 million (up 3.44% YoY), and the FY2025 full-year result was $56.0 million, up 3.67% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $57.3 million, up from $56.0 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $57.3 million in Q1 2026 and bottomed at $32.6 million in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $53.5 million (2024), against an average of $49.6 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) jumped 61.09%; it then climbed 1.9% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $37.6 million in 2022, then soared by 40.22% to $52.7 million in 2023, then grew by 2.53% to $54.0 million in 2024, then grew by 3.67% to $56.0 million in 2025, then increased by 2.25% to $57.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $57.3 million (Q1 2026), $56.0 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 57.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.28 Mn |
| Dec 31, 2025 | 56.02 Mn |
| Sep 30, 2025 | 56.28 Mn |
| Jun 30, 2025 | 56.03 Mn |
| Mar 31, 2025 | 55.38 Mn |
| Dec 31, 2024 | 54.04 Mn |
| Sep 30, 2024 | 53.87 Mn |
| Jun 30, 2024 | 53.74 Mn |
| Mar 31, 2024 | 53.52 Mn |
| Dec 31, 2023 | 52.70 Mn |
| Sep 30, 2023 | 52.60 Mn |
| Jun 30, 2023 | 52.57 Mn |
| Mar 31, 2023 | 52.53 Mn |
| Dec 31, 2022 | 37.59 Mn |
| Sep 30, 2022 | 33.83 Mn |
| Jun 30, 2022 | 32.79 Mn |
| Mar 31, 2022 | 32.61 Mn |
| Dec 31, 2021 | 30.90 Mn |
| Sep 30, 2021 | 32.13 Mn |
| Jun 30, 2021 | 29.68 Mn |
| Mar 31, 2021 | 29.41 Mn |
| Dec 31, 2020 | 22.39 Mn |
| Sep 30, 2020 | 21.93 Mn |
| Jun 30, 2020 | 20.63 Mn |
| Mar 31, 2020 | 19.56 Mn |
| Dec 31, 2019 | 18.16 Mn |
| Sep 30, 2019 | 18.66 Mn |
| Jun 30, 2019 | 17.45 Mn |
| Mar 31, 2019 | 17.22 Mn |
| Dec 31, 2018 | 16.00 Mn |
| Sep 30, 2018 | 17.47 Mn |
| Jun 30, 2018 | 14.38 Mn |
| Mar 31, 2018 | 14.37 Mn |
| Dec 31, 2017 | 9.27 Mn |
| Sep 30, 2017 | 335,285.00 |
| Jun 30, 2017 | 334,788.00 |
| Mar 31, 2017 | 330,075.00 |
| Dec 31, 2016 | 312,169.00 |
| Sep 30, 2016 | 318,948.00 |